RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. Since then, owing to...

The global miRNA tools and services market, valued at USD 519.71 million in 2024, is projected to reach USD 629.69 million in 2025 and USD 2,940.53 million by 2035, representing a CAGR of 16.7% during the forecast period. miRNA tools and services market report, presently research tools account for the largest share (72%) of the market. According to our miRNA tools and services market analysis, presently qRT-PCR occupies the highest share (25%) of the market. North America is dominating the marke...

The CDK4 / 6 inhibitors market is estimated to grow from USD 11.34 billion in 2024 to reach USD 13.51 billion in 2025 and USD 55.92 billion by 2035, representing a higher CAGR of 15.3% during the forecast period. According to the Breast Cancer Facts and Statistics, in 2025, nearly 3,16,950 women will be diagnosed with invasive breast cancer. According to CDK4 / 6 inhibitors market analysis, currently North America is dominating the market by holding 45% of the overall revenue share.

Estimates suggest that, in 2022, the adoption of AI-based solutions for drug discovery are likely to enable savings worth USD 8.57 billion, with market projections suggesting cost savings of USD more than 28 billion by 2035. Even though only a few of such AI-based platforms have gone public, developers have experienced considerable growth in share value as their respective platforms / product candidates progressed through the various stages of development. Usually, a prescription drug requires a...

The global DNA and gene cloning services market, valued at USD 3.12 billion in 2025, is projected to reach USD 3.57 billion in 2026 and USD 14.55 billion by 2035, with a 16.9% CAGR during the forecast period 2026 to 2035. Over time the continuous advancements in genetic engineering and cloning have opened up exciting possibilities for scientists. For instance, gene cloning can help to make therapies for diseases such as cystic fibrosis, cancer, and AIDS. Additionally, gene cloning presents a fa...

The global Fc and glycoengineered antibodies market, valued at USD 42.3 billion in 2025, is projected to reach USD 45.7 billion in 2026 and USD 38.7 billion by 2035, during the forecast period 2026 to 2035. Antibody based pharmacological interventions have become one of the fastest growing segments of the biopharmaceutical industry, with over 120 approved monoclonal antibodies, and close to 900 registered trials for clinical evaluation. In fact, it is worth highlighting that, these interven...

The global DNA synthesis market, valued at USD 1.20 billion in 2025, is projected to reach USD 1.46 billion in 2026 and USD 8.63 billion by 2035, with a 22% CAGR during the forecast period 2026 to 2035. It is worth mentioning that a significant driver propelling the global DNA synthesis market is the increasing requirement for synthetic oligonucleotides such as DNA or RNA to develop therapies, including gene therapies, RNA-based therapies, and targeted therapies. Driven by the growing usage of...

The global digital biomarkers market, valued at USD 5.6 billion in 2024, is estimated to reach USD 7.4 billion in 2025 and USD 35.8 billion by 2035, representing a CAGR of 17.0% during the forecast period. It is estimated that 65% of hospital patients and more than 90% of post-acute care patients are manually tracked for vitals and patient-specific parameters, every four to eight hours. As a result, there has been a rising prominence of telemedicine that leverages digital tools in order to provi...

The coronary drug eluting stent market, valued at USD 4.04 billion in 2025, is projected to reach USD 4.50 billion in 2026 and USD 9.38 billion by 2035, with a 8.51% CAGR during the forecast period 2026 to 2035. According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders. In fact, in 2020 (post the onset of the pandemic), a more than 3% increase in the deaths related to heart diseases was reported. Notably, cardiac stents ar...

The antibiotics market size, valued at USD 37 billion in 2025, is projected to reach USD 37 billion in 2026 and USD 41 billion by 2035, representing a CAGR of 1.2% during the forecast period 2026 to 2035. In terms of type of drug class, the other drug class segment secures >60% of the overall revenue share of the global market. Antibiotics has two types of therapies, such as monotherapies and combination therapies. Of which, monotherapy holds the majority of the share (~80%). With regards to t...

The global gene switch market, valued at USD 795 million in 2025, is projected to reach USD 899 million in 2026 and USD 2,478 billion by 2035, with a 11.93% CAGR during the forecast period 2026 to 2035. Notably, in the past few years, close to 30 cell and gene therapy products have been approved by the US FDA. In addition, over 1,200 cell therapies are currently being evaluated across various clinical stages of development. However, despite various advantages, adverse events are associated with...

The global cell and gene therapy supply chain software market, valued at USD 312 million in 2025, is projected to reach USD 356 million in 2026 and USD 1,329 million by 2035, representing a CAGR of 15.8% during the forecast period 2026 to 2035. According to a report published by Novotech, it was anticipated that more than 12 novel cell and gene therapies would be approved by the end of 2023, highlighting lucrative opportunities for stakeholders in this market. Moreover, post-2018, over 40% of th...

he broader focus will be on the development of tailored therapeutic drugs, including gene therapies, companion animal vaccines and recombinant proteins that can address animal’s unique needs.For instance, in February 2025, Bharat Biotech (India) announced that its Biolumpivaxin (vaccine for lumpy skin disease) has received the Central Drug Standards Control Organization license for cattle’s and buffaloes. As more market players continue to develop advanced biologics, it is expected that vete...

The global protein expression market, valued at USD 3.0 billion in 2025, is projected to reach USD 3.2 billion in 2026 and USD 6.3 billion by 2035, with a 7.8% CAGR during the forecast period 2026 to 2035. Over the years, proteins have become increasingly important for their application as therapeutic candidates, owing to their versatility, enhanced metabolic stability, biological target specificity and higher affinity. It is important to note that 50% of the top ten selling drugs are protein th...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The global complementary and alternative medicine market, valued at USD 160.65 billion in 2024, is projected to reach USD 209.67 billion in 2025 and USD 1,605.23 billion by 2035, representing a CAGR of 22.6% during the forecast period. Currently, traditional alternative medicine accounts for the highest complementary and alternative medicine share (over 35%). Among these, herbal supplements hold the highest complementary and alternative medicine market size (with a share of 40%). Pain managemen...

The global antimalarial drugs market size, valued at USD 1.13 billion in 2024, is projected to reach USD 1.19 billion in 2025 and USD 1.75 billion by 2035, representing a CAGR of 3.9% during the forecast period. The antimalarial drug industry is constantly witnessing an upward trajectory as players are focusing on the development of resistance-free antimalarial drugs to mitigate the concern of drug resistance. A recent success in antimalarial drugs has been shared by the Karine Le Roche, (profes...

Major players like AstraZeneca (UK), Pfizer (US), Merck (US), and Roche (Switzerland) are making significant investments to achieve sustainability goals and reduce their environmental impact. They are adopting strategies such as green chemistry, renewable energy integration, and upgrading manufacturing facilities.Roche (Switzerland) has committed a massive investment of USD 50 billion over five years into its US pharmaceutical and diagnostics operations. This investment includes expanding and up...

The probiotics market, valued at USD 70.9 billion in 2024, is project to reach USD 76.2 billion in 2025 and USD 165.1 billion by 2035, representing a CAGR of 8.0% during the forecast period 2025 to 2035. In terms of type of product, the food and beverages segment holds the highest share (nearly 80%) of the market.  The nutritional supplements segment is capturing the majority of the market share (~60%) in the year 2025, with respect to type of probiotic dietary supplement segment. In terms o...

The NGS-based RNA-sequencing market is estimated to grow from USD 3.59 billion in 2024 to reach USD 4.41 billion in 2025 and USD 22.44 billion by 2035, representing a CAGR of 17.7% during the forecast period. According to our NGS-based RNA-sequencing market report, presently, the consumables segment is holding the maximum share (53.02%) of the market. Notably, this trend of dominance is likely to remain unchanged during the forecast period. This can be attributed to the high demand of consumable...